

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>OTPE</small>		Application Number	10/016,985
		Filing Date	12/07/01
		First Named Inventor	Walke
		Group Art Unit	1645 1652
		Examiner Name	To be assigned
		Attorney Docket Number	LEX-0273-USA
<small>Use as many sheets as necessary</small>			
Sheet	1	of 400	3 (C)

## U.S. PATENT DOCUMENTS

7/11/04

**\*EXAMINER:** Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/016,985
(use as many sheets as necessary)			Filing Date	12/07/01
APR 19 2002			First Named Inventor	Walke
			Group Art Unit	1645 1652
			Examiner Name	To be assigned <i>Masahisa</i>
Sheet	2	of	3	Attorney Docket Number
LEX-0273-USA				

TECH CENTER 1600-2800 APR 23 2002

RECEIVED

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
RE.R.	AZ	Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", <i>Science</i> 242:423-426.		
RE.R.	BA	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", <i>Methods in Enzymology</i> 153:516-544.		
RE.R.	BB	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", <i>J. Mol. Biol.</i> 150:1-14.		
RE.R.	BC	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetraethylimidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", <i>Nucleic Acids Research</i> 15(16):6625-6641.		
RE.R.	BD	Gordon, 1989, "Transgenic Animals", <i>International Review of Cytology</i> , 115:171-229.		
RE.R.	BE	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", <i>FASEB Journal</i> 7:437-444.		
RE.R.	BF	Gu et al, 1994, "Deletion of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting", <i>Science</i> 265:103-106.		
RE.R.	BG	Huse et al, 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", <i>Science</i> 246:1275-1281.		
RE.R.	BH	Huston et al, 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ", <i>Proc. Natl. Acad. Sci. USA</i> 85:5879-5883.		
RE.R.	BI	Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", <i>FEBS Letters</i> 215(2):327-330.		
RE.R.	BJ	Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides", <i>Nucleic Acids Research</i> 15(15):6131-6149.		
RE.R.	BK	Inouye & Inouye, 1985, "Up-promoter mutations in the <i>lpp</i> gene of <i>Escherichia coli</i> ", <i>Nucleic Acids Research</i> 13(9):3101-3110.		
M.M.	BL	Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", <i>PNAS</i> 88:8972-8976.		
M.M.	BM	Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", <i>Nature</i> 256:495-497.		
M.M.	BN	Lakso et al, 1992, "Targeted oncogene activation by site-specific recombination in transgenic mice", <i>Proc. Natl. Acad. Sci. USA</i> 89:6232-6236.		
M.M.	BO	Lavitrano et al, 1989, "Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice", <i>Cell</i> 57:717-723.		
M.M.	BP	Lo, 1983, "Transformation by Iontophoretic Microinjection of DNA: Multiple Integrations without Tandem Insertions", <i>Mol. Cell Biology</i> 3(10):1803-1814.		
RE.R.	BQ	Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", <i>Proc. Natl. Acad. Sci. USA</i> 81:3655-3659.		
RE.R.	BR	Lowy et al, 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", <i>Cell</i> 22:817-823.		

Examiner Signature	<i>Rehman</i>	Date Considered	4/11/04
--------------------	---------------	-----------------	---------

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/016,985	
(use as many sheets as necessary)			Filing Date	12/07/01	
APR 19 2002			First Named Inventor	Walke	
			Group Art Unit	1645 1652	
			Examiner Name	To be assigned	
Sheet	3	of	3	Attorney Docket Number	LEX-0273-USA

RECEIVED  
SEARCH CENTER  
160200

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
RE. RE.	BS	Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA 81:6851-6855.			
RE. RE.	BT	Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.			
RE. RE.	BU	Neuberger et al, 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.			
RE. RE.	BV	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of Immunology 147:2429-2438.			
RE. RE.	BW	O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.			
RE. RE.	BX	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.			
RE. RE.	BY	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.			
RE. RE.	BZ	Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.			
RE. RE.	CA	Smith et al, 1983, "Molecular Engineering of the <i>Autographa californica</i> Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.			
RE. RE.	CB	Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.			
RE. RE.	CC	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.			
RE. RE.	CD	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.			
RE. RE.	CE	Thompson et al, 1989, "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting in Embryonic Stem Cells", Cell 56:313-321.			
M. M.	CF	Van Der Putten et al, 1985, "Efficient insertion of genes into the mouse germ line via retroviral vectors", Proc. Natl. Acad. Sci. USA 82:6148-6152.			
RE. RE.	CG	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in <i>Escherichia coli</i> ", J. Biol. Chemistry 264(10):5503-5509.			
RE. RE.	CH	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ", Nature 341:544-546.			
RE. RE.	CI	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223-232.			
RE. RE.	CJ	Wigler et al, 1980, "Transformation of mammalian cells with an amplifiable dominant-acting gene", Proc. Natl. Acad. Sci. USA 77(6):3567-3570.			

Examiner Signature	<i>RE. RE. Walsh</i>	Date Considered	4/10/04
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



